Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

A trader selling the November 10th, $76-strike put on GILD would receive around $105 into their account, which would be theirs to keep.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Promising Biotech Stocks for Smart Investment Strategies

The biotechnology industry is flourishing due to the recent strides in drug formulation, technological advancements, and unwavering government support. Given this backdrop, promising biotech stocks United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD) present smart investment options to garner significant returns. Read on….

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks with Breakout Growth Potential

Fueled by a combination of technological breakthroughs and unparalleled data accessibility, the biotechnology industry is poised for growth in the long term. Hence, fundamentally strong biotech stocks Theratechnologies (THTX), Shionogi (SGIOY), and Gilead Sciences (GILD), which show solid growth potential, might be worth buying. Read on.

StockNews.com

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

StockNews.com

Top 3 Tech Stocks in the A-Rated Industry on Wall Street

From groundbreaking advancements to transformative trends, the tech sector has comfortably navigated macroeconomic headwinds. As the demand for technology products and services rises, it could be wise to check out top tech stocks Cognizant Technology Solutions (CTSH), Gartner (IT), and Hackett Group (HCKT) from an A-rated industry. Read on….

StockNews.com

2 Biotech Stocks You Should Buy While You Can, 1 That Investors Are Avoiding

The biotech industry is well-positioned for solid growth, thanks to the rising need for high-quality healthcare and the government's push to increase domestic biotech production and research. To that end, buying fundamentally strong biotech stocks Gilead Sciences (GILD) and Jazz Pharmaceuticals (JAZZ) could be wise. However, it could be prudent…

StockNews.com

3 Biotech Stocks to Buy for August

The biotechnology sector has experienced extraordinary expansion, largely due to technological advancements that continue to position the industry as a pioneering influencer in crucial areas of healthcare, agriculture, and environmental stability. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) could be solid…

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Every Investor Wants

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

StockNews.com

2 Game-Changing Biotech Stocks, 1 to Sell Now

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

StockNews.com

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

StockNews.com

2 of the BEST S&P 500 Stocks by One-Year Performance

While macroeconomic uncertainties have fostered market volatility, the S&P 500 gained 7.8% year-to-date. We think fundamentally strong S&P 500 stocks Gilead Sciences (GILD) and Marathon Petroleum (MPC), which have gained more than 30% over the past year, could be worth buying now. Read more.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Stocks with More Upside Potential

Coupled with macroeconomic headwinds, the sudden regional banking failures have marred investor sentiments. Moreover, amid anticipations of a recession, the existing market volatilities are not likely to subside anytime soon. Given this backdrop, we think the strong growth prospects of Gilead Sciences (GILD), Teva Pharmaceutical (TEVA), and MacroGenics (MGNX) make…

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

3 Nasdaq Stocks That Could Carry Your Portfolio for Years

With the broader market in trepidation amid the ongoing turmoil in the banking sector, fundamentally strong and resilient Nasdaq stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Autodesk (ADSK) could be worth investing in for sustained risk-adjusted returns. Continue reading….

StockNews.com

3 Value Stocks You Won't Regret Buying in 2023

With the Fed’s measures to counter inflation causing the collateral damage of asset price deflation, it could be wise to load up on Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), and DoubleDown Interactive (DDI), available at attractive valuations to capture future upside potential while limiting downside risks. Continue reading….

StockNews.com

2 Smart Dividend Stocks to Buy Now for Steady Gains

With the stock market expected to remain volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally strong dividend stocks Gilead Sciences (GILD) and Altria (MO) might be ideal choices to ensure a consistent income stream. Keep reading.

1 … 3 4 5 6

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Steve Reitmeister

508 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.